Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells
出版年份 2023 全文链接
标题
Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells
作者
关键词
-
出版物
Proteomics Clinical Applications
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-09-07
DOI
10.1002/prca.202300061
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Global challenges and policy solutions in breast cancer control
- (2022) Dario Trapani et al. CANCER TREATMENT REVIEWS
- RAB5C, a new mRNA binding target of HuR, regulates breast cancer cell proliferation
- (2022) Zhenzhen Wang et al. CELL BIOLOGY INTERNATIONAL
- HIPK2 in cancer biology and therapy: Recent findings and future perspectives
- (2022) Andrea Conte et al. CELLULAR SIGNALLING
- Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit sensitivity to PI3Kα inhibitors
- (2021) Yanyan Cai et al. CANCER RESEARCH
- Precision medicine in breast cancer: from clinical trials to clinical practice
- (2021) Edoardo Crimini et al. CANCER TREATMENT REVIEWS
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
- (2021) H.J. Burstein et al. ANNALS OF ONCOLOGY
- Anticancer drug resistance: An update and perspective
- (2021) Ruth Nussinov et al. DRUG RESISTANCE UPDATES
- Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
- (2020) Andriy Marusyk et al. CANCER CELL
- The role of genomics in global cancer prevention
- (2020) Ophira Ginsburg et al. Nature Reviews Clinical Oncology
- mTORC1 promotes TOP mRNA translation through site-specific phosphorylation of LARP1
- (2020) Jian-Jun Jia et al. NUCLEIC ACIDS RESEARCH
- Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications
- (2020) Xiaobin Zeng et al. PHARMACOLOGICAL RESEARCH
- Prevalence and role of HER2 mutations in cancer
- (2019) Emiliano Cocco et al. PHARMACOLOGY & THERAPEUTICS
- Consensus sequence design as a general strategy to create hyperstable, biologically active proteins
- (2019) Matt Sternke et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2
- (2019) Martiniano Bello et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
- (2019) Lillian M. Smyth et al. Cancer Discovery
- Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women
- (2018) Ranjit Manchanda et al. JNCI-Journal of the National Cancer Institute
- Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women
- (2018) Ranjit Manchanda et al. JNCI-Journal of the National Cancer Institute
- Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
- (2018) Sarah Croessmann et al. CLINICAL CANCER RESEARCH
- Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
- (2018) Emiliano Cocco et al. Science Signaling
- Mutation effects predicted from sequence co-variation
- (2017) Thomas A Hopf et al. NATURE BIOTECHNOLOGY
- LARP1 functions as a molecular switch for mTORC1-mediated translation of an essential class of mRNAs
- (2017) Sungki Hong et al. eLife
- Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis
- (2016) Jill A. Opsahl et al. PROTEOMICS
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- A method and server for predicting damaging missense mutations
- (2010) Ivan A Adzhubei et al. NATURE METHODS
- MutationTaster evaluates disease-causing potential of sequence alterations
- (2010) Jana Marie Schwarz et al. NATURE METHODS
- EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
- (2008) T. Trowe et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now